Excellent
Aligned
Patient Risk:
Low
Summary
All key WARNING: OCULAR TOXICITY statements evaluated are directly supported by the provided BLENREP prescribing information excerpts (ocular toxicity definition, incidence, specific adverse reactions, corneal ulcer guidance, ophthalmic monitoring, and REMS linkage). No contradictions are identified.
Category Scores
Accurate Statements
BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions.
Supported by label section 5.1 (Ocular Toxicity definition).
In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77%; most common ocular toxicities included reduction in BCVA (89%) and corneal exam findings (86%), with blurred vision (66%) and dry eye (51%).
Supported by label section 5.1 and Table/clinical trial data referenced therein.
Cases of corneal ulcer, including cases with infection, have been reported and should be managed promptly by an eye care professional.
Supported by label section 5.1.
Ophthalmic exams (slit lamp exam and BCVA assessment) should be conducted at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated, by an eye care professional.
Supported by label sections 5.1 and 2.1.
Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less, then resume at same or reduced dose or permanently discontinue based on severity.
Supported by label sections 5.1 and 2.3.
BLENREP is available only through a restricted program under a REMS because of ocular toxicity risk, including requirements for prescriber counseling and ophthalmic monitoring before each dose.
Supported by label section 5.2 (REMS) and 5.1 linkage.
Unsupported Statements
Contradictions
Important Omissions
None identified that are material to the evaluated WARNING: OCULAR TOXICITY claim based on the provided label excerpts (5.1, 5.2, 2.1, 2.3, 6.1).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Evaluated content accurately reflects on-label warning elements and associated monitoring/dose modification guidance for ocular toxicity; no incorrect or conflicting safety claims were made in the provided evaluation text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement